Enveric Biosciences (ENVB) Capital Expenditures (2016 - 2023)
Enveric Biosciences (ENVB) posted Capital Expenditures of -$15.0 for Q4 2023, down 287.5% sequentially from $8.0 in Q3 2023, and down 100.24% YoY from $6193.0 in Q4 2022.
Enveric Biosciences (ENVB) Capital Expenditures (2016 - 2023) Analysis & Trends
Enveric Biosciences has reported Capital Expenditures for 7 years, with the latest figure at -$15.0 in Q4 2023.
- Quarterly Capital Expenditures fell 100.24% year-over-year to -$15.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $5180.0 (down 99.11% YoY) and the FY2023 annual result came in at $5180.0, down 99.11% from the prior year.
- Capital Expenditures eased to -$15.0 in Q4 2023 per ENVB's latest filing, from $8.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $505507.0 in Q1 2022 and troughed at -$3405.0 in Q2 2020.
- A 4-year average of $51415.1 and a median of $9058.0 in 2019 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2019 and 2020: Capital Expenditures jumped 414.96% in 2019, then tumbled 121.58% in 2020.
- Over 4 years, Capital Expenditures stood at $56633.0 in 2019, then sank by 89.11% to $6167.0 in 2020, then climbed by 0.42% to $6193.0 in 2022, then slumped by 100.24% to -$15.0 in 2023.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$15.0, $8.0, and $18.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -15.00 |
| Dec 31, 2023 | -15.00 |
| Sep 30, 2023 | 8.00 |
| Sep 30, 2023 | 8.00 |
| Jun 30, 2023 | 18.00 |
| Jun 30, 2023 | 18.00 |
| Mar 31, 2023 | 5,169.00 |
| Mar 31, 2023 | 5,169.00 |
| Dec 31, 2022 | 6,193.00 |
| Dec 31, 2022 | 6,193.00 |
| Sep 30, 2022 | 18,574.00 |
| Sep 30, 2022 | 18,574.00 |
| Jun 30, 2022 | 53,891.00 |
| Jun 30, 2022 | 53,891.00 |
| Mar 31, 2022 | 505,507.00 |
| Mar 31, 2022 | 505,507.00 |
| Sep 30, 2020 | 6,167.00 |
| Sep 30, 2020 | 6,167.00 |
| Jun 30, 2020 | -3,405.00 |
| Jun 30, 2020 | -3,405.00 |